Introduction
The increase in the prevalence of obesity is becoming a public health problem that is due, in part, to the associated diseases type 2 diabetes, hypertension, hyperlipidemia and atherosclerosis (Lovejoy et al., 1996; Vague, 1956) . Visceral obesity is a risk factor for this cluster of metabolic and vascular dysfunctions that is independent of the risk conferred by overall obesity (Wajchenberg, 2000) . Abnormal fat accumulation is linked with an increase in the number and size of adipocytes, so it is important to study factors involved in this aspect of fat accumulation.
MicroRNAs have recently been identified as a novel RNA species that is involved in gene regulation. These evolutionarily conserved noncoding RNAs, of approximately 22 nucleotides in length, typically inhibit expression of their target mRNAs by lowering the stability of these mRNAs and/or the efficiency of their translation via the RNA-induced silencing complex (Grishok et al., 2001) . MicroRNAs are involved in many processes, including cell survival and death (Hutvagner et al., 2001) , lipid and glucose metabolism Kornfeld et al., 2013) and tissue development (Fu et al., 2013) .
Human preadipocytes are a useful in vitro model for investigating adipocyte proliferation and differentiation at the molecular level (Flier, 2004) . Preadipocytes from different human fat depots show substantial variation in size, function, differentiation capacity, and in the gene expression profiles of glucose and lipid metabolism genes (Shahparaki et al., 2002; Tchkonia et al., 2006 Tchkonia et al., , 2007 Tchkonia et al., , 2005 . Therefore, to understand how visceral fat tissue accumulates excess fat, human visceral preadipocytes isolated from omental adipose tissue should be studied. However, there is currently limited data available on microRNA level and function changes during human visceral adipogenesis.
We identified differentially expressed miRNAs during the three different stages of adipogenesis, human mesenchymal stem cells (hMSCs), human visceral preadipocytes (vHPA) and mature adipocytes by miRNA microarray analysis (unpublished data, details are available upon request). Subsequently, miRNA expression validation by qRT-PCR revealed miR-146b was a miRNA highly in mature adipocytes while very lowly expressed in hMSCs and vHPA. To our knowledge, the function of miR-146b in human visceral adipogenesis is unknown. Therefore, in this paper, we mainly focused on the roles of miR-146b in human visceral adipogenesis.
Materials and methods

Cell culture and adipocytes differentiation
hMSCs and vHPA from Sciencell Research Laboratories (San Diego, CA, USA) were cultured in preadipocyte medium (PAM; Sciencell Research Laboratories) supplemented with 5% fetal bovine serum (FBS), 1% preadipocyte growth supplement (PAGS) and 1% penicillin/streptomycin solution (P/S) at 37°C in 5% CO 2 . The HEK293T cells were grown in Dulbecco's modified Eagle's medium (DMEM; WISENT, Canada) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin solution (P/S) (WISENT). To induce differentiation, hMSCs or vHPA were cultured to full confluence and then maintained in differentiation medium (serum-free PAM containing 5 lg/ml insulin, 1 lM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine and 1 lM rosiglitazone (Sigma, St. Louis, MO, USA)) for the first 4 days. Then, the medium was replaced with serum-free PAM containing 5 lg/ml insulin, which was changed every 3 days until the accumulation of large lipid droplets were observed.
Blood biochemistry
Serum total cholesterol, total triglyceride, HDL-C, LDL-C, ApoA1, ApoB and glucose levels were all determined with Olympus Chemistry Analyzer AU2700 (Olympus, USA) by the clinical laboratory in Nanjing Maternity and Child Health Care Hospital.
Expression vectors for use in human preadipocytes
MiR-146b overexpression and negative control vectors were constructed, and produced as described previously (Chen et al., 2013) . Anti-miR46b lentivirus and negative control lentivirus were purchased from Gene Pharma (Shanghai, China). Unless stated otherwise, cells were seeded onto 6 or 12 well plates (Corning, New York, USA) at a density of 105-106 cells/well, and 24 h later were infected either with the miR-146b overexpression/knockdown lentivirus or with the negative control in 5 lg/ml polybrene (Sigma).
Oil red O staining
After cells had been allowed to differentiate to mature adipocytes for 13 days, they were washed with 1Â PBS and fixed with 4% formaldehyde for 10 min. After fixation, the cells were washed again in 1Â PBS and stained for 30 min at 37°C with 0.2% oil red O. Then, the oil red O was removed and the cells were gently rinsed in water several times. Finally, the plates were observed under the microscope (Olympus, Tokyo, Japan).
Triglyceride assay
The intracellular triglyceride content was measured using a tissue triglyceride assay kit (Applygen, Beijing). The mature cells, at day 13 of differentiation, were harvested in lysis buffer and the cell lysates were collected and homogenized. Then, the cell suspension was used for the triglyceride analysis according to the manufacturer's instructions.
Cell proliferation assay
For the cell proliferation assay, a WST-8 Cell Counting Kit-8 was used (CCK-8; Dojindo, Japan). Human preadipocytes were first transfected with either the miR-146b overexpression/knockdown lentivirus or the negative control lentivirus in 12-well culture plates. After infection for 48 h, isolated cells were seeded onto 96-well culture plates at a density of 600 cells/well in 100 ll PAM medium. After 36 h of incubation, cells were analyzed at the following time points: 48 h, 60 h, 72 h and 84 h. The old culture medium was removed, 100 ll of fresh culture medium containing 10 ll CCK-8 was added to each well of the 96-well assay plates, and the cells were cultured for 1 h at 37°C in 5% CO 2 . The absorbance at 450 nm was measured using a DNM-9602 microplate reader (Perlong, China).
Cell cycle analysis
Preadipocytes were cultured in 6-well culture plates and transfected with either miR-146b overexpression lentivirus or the negative control lentivirus. After being infected for 48 h, cells were serum-deprived for 12 h for cell cycle synchronization, and then incubated in PAM medium containing 5% FBS for another 36 h. Then, cells were harvested and fixed in 70% ethanol at 4°C overnight. Subsequently, cells were treated with RNase A (100 lg/ml) and propidium iodide (50 lg/ml) at 37°C for 30 min, and analyzed using the FACStar cell sorter and Cell QUEST Pro (BD FACSCalibur, Mountain View, CA, USA).
Luciferase reporter assay to determine the interaction of miR-146b with the KLF7 gene
The 3 0 UTR sequence of the human KLF7 gene that contains the predicted miR-146b binding site, or a mutant 'seed' sequence, was generated by PCR and inserted downstream of the luciferase gene in the psi-CHECK2 vector (Promega Corporation, USA). The two constructs were termed W.T.KLF7-3 0 UTR and M.T.KLF7-3 0 UTR, respectively. The sequences of the miR-146b-binding site and mutant site in the KLF7 gene are:
In the luciferase assays, either the W.T.KLF7-3 0 UTR or the M.T.KLF7-3 0 UTR vector, along with the miR-146b overexpression plasmid or negative control were transiently transfected into HEK 293T cells cultured in 96-well plates using Lipofectamine2000 (Invitrogen) according to the manufacturer's instructions. After 48 h transfection, cell lysates were analyzed for luciferase activity using the Dual-luciferase Reporter Assay System (Promega Corporation).
Diet-induced obese mouse model
All experiments were approved by the Nan Jing Medical University Animal Experiment Ethics Committee. Mice were housed in a temperature-controlled room (22-25°C) with 12-h light/dark cycles, and had free access to food and water. Totally twenty male C57BL/6N mice (aged 8 weeks) were used. The mice were divided into two groups of 10 mice: one group was fed a high fat diet (HFD; 60 kcal% fat; Research Diets, New Brunswick, NJ, USA) for 17 weeks; the other group of mice was fed a normal chow diet (NCD; 10 kcal% fat). Body weight measurements were taken weekly. At the end of the experiment, an evaluation of blood glucose intolerance and insulin sensitivity was performed as described previously (Chartoumpekis et al., 2011) . White adipose tissue was excised from the subcutaneous and epididymal fat pads, and brown fat tissue (BAT) was extracted from the interscapular regions of NCD or HFD mice. These tissues were immediately submerged in liquid nitrogen and stored at À80°C for miR-146b expression level analysis.
Human subjects
A total of 36 subjects undergoing surgery because of various disorders were enrolled. Patients with endocrine disorders, malignancy or severe systemic illness were excluded. The subjects were divided into two groups, based on BMI: lean subjects (18.5 < BMI < 23.9 kg/m 2 , n = 21) and overweight or obese subjects (BMI P 24 kg/m 2 , n = 15). Depending on the different types of surgery carried out on the subject, either subcutaneous white adipose tissue or/and visceral white adipose tissue was isolated. Biopsies were snap-frozen and stored at À80°C until RNA isolation. All subjects provided a written informed consent to participate in the study, and the research protocol was approved by the Ethics Committee of Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University in China -50, No. 2013 .
Real-time quantitative PCR analysis
Cultured cells were collected with Trizol, and RNA was extracted using the miRNeasy Mini Kit (QIAGEN, USA) according to the manufacturer's instructions. The quality of RNA was checked using 0.8% agarose gel electrophoresis, and the concentration was quantified by measuring the absorbance at 260 nm in a OneDrop SpectroPhotometer (Gene Company Ltd., Shanghai, China).
For microRNA analysis, 200 ng of total RNA was reverse-transcribed by using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. For real-time PCR, miR-146b levels were analyzed as follows: 1 ll (1:20 dilution) of cDNA, 0.1 lM TaqMan probe, 0.2 lM forward primer, 0.2 lM reverse primer and TaqMan Universal PCR Master Mix II (Applied Biosystems) were included in 20 ll reactions, using the following reaction conditions: 10 min at 95°C, then 40 cycles of 15 s at 95°C and 1 min at 60°C. Small nucleolar RNA U6 (snRU6) was used as the normalizing control. All primers were designed and synthesized by Applied Biosystems.
For the marker gene expression levels assay, 2 lg of total RNA was reverse-transcribed into cDNA using the M-MLV First Strand Kit (Invitrogen). Reaction conditions were as described in the manufacturer's instructions. Real-time PCR was performed as described for the microRNA analysis. Expression levels were normalized to the expression level of 18S RNA. All primers used are listed in Table 1 . All real-time PCR reactions were run on an ABI PRISM 7500 Sequence Detector (Applied Biosystems).
Western blot
Cells were collected in lysis buffer (20 mM Tris-HCl (PH 8.0),150 mM NaCl, 10% glycerol, 20 mM beta-glycerol phosphate, 1% NP-40, 5 mM EDTA, 0.5 mM EGTA) supplemented with protease inhibitors (Roche Applied Science, Germany). Protein concentrations of the extracts were analyzed by BCA protein assay (Thermo Fisher Scientific, Waltham, MA). The extracts were boiled with 4Â SDS loading buffer (150 mM Tris-HCl (pH 6.8), 12% SDS, 30% glycerol, 0.02% bromophenol blue, 6% 2-mercaptoethanol) at 95°C for 10 min, then 30 lg protein was subjected to 10% SDS-PAGE, transferred to 0.2 lm PVDF membrane (Millipore, USA), and used to immunoblot analysis. Membranes were incubated overnight with primary antibodies against KLF7 (Cat. No. H00008609-A01, Abnova, Taiwan, China) and b-Actin (Cat. No. BS6499, Bioworld, China).
Statistical analysis
Each experiment was performed at least three times. All values are presented as means ± SEM or SD of three or more independent experiments. The relationships between BMI and miR-146b levels were analyzed using SPSS 17.0 and the coefficients of correlation were investigated using Pearson's linear regression analysis. Differences were considered statistically significant at P < 0.05 using the Student's t-test.
Results
MiR-146b expression in adipogenesis
Quantitative RT-PCR was used to test the expression changes between mature adipocytes and hMSCs or vHPA. In mature adipocytes, miR-146b expression levels increased by approximately 70.1-fold and 8.72-fold compared with the levels found in hMSCs and vHPA, respectively ( Fig. 1A and B) .
MiR-146b expression was investigated during human adipocyte differentiation. As shown in Fig. 1C , the level of miR-146b gradually increased throughout adipogenesis and reached its highest level at day 13 of differentiation. These results suggest that miR146b is highly expressed in mature adipocytes, and its expression might be linked with the development of adipocytes.
MiR-146b promotes human adipocytes differentiation
To investigate whether the miR-146b has a functional role in adipocyte differentiation, the miR-146b overexpression lentivirus was firstly transfected into human visceral preadipocytes. Then, qRT-PCR analysis was used to measure the abundance of miR146b 48 h post transfection. The success of miR-146b overexpression is demonstrated in Fig. 2A as the miR-146b expression level was elevated almost 4.3-fold compared with the mock lentivirusinfected cells. Oil red O staining and the TG assay were used to assess the effects of miR-146b on lipid accumulation. Overexpression of miR-146b resulted in promotion of adipocytes differentiation, as determined by morphological changes observed using cell staining with oil red O at day 13 of differentiation ( Fig. 2B) . This result is consistent with the increase observed in TG production (Fig. 2C) . Besides, we investigated changes in the expression levels of key adipogenic transcription factors and adipocyte-specific genes, including C/EBPa, PPARc, AP2, GLUT4 and HSL, at days 0, 1, 4, 7, 10 and 13 after the induction of differentiation. Overexpression of miR-146b significantly elevated the expression of the transcription factors C/EBPa and PPARc at day 7 (Fig. 2D) . The expression levels of GLUT4, HSL and AP2 were also elevated at this time point. The expression levels of PPARc remained consistently higher in the miR-146b overexpressing cells than in the control lentivirus transduced cells until the end of the experiment on day 13. On the contrary, infection with anti-miR46b lentivirus decreased miR-146b level about 0.5-fold in human visceral preadipocytes (Fig. 3A) , and inhibited adipocytes differentiation by Oil red O staining (Fig. 3B ) and the TG assay (Fig. 3C) . Meanwhile, expression levels of C/EBPa, PPARc, AP2, GLUT4 and HSL were decreased at different time points during adipogenesis (Fig. 3D) .
MiR-146b inhibits human adipocyte proliferation by affecting the cell cycle
In order to determine whether miR-146b expression is involved in the proliferation of preadipocytes, we firstly overexpressed miR146b in vHPA and then analyzed the numbers of cultured cells present over an 84 h period using a CCK-8 assay. As shown in Fig. 4 A, after 48 h, the OD 450 nm value of the miR-146b overexpression group was lower than the negative control group, indicating that increased miR-146b levels can inhibit human adipocyte proliferation. In contrast, down-regulation of miR-146b had no effect on proliferation of human visceral preadipocytes (Fig. S2) .
To explore this suppression of cell proliferation by miR-146b, we examined the distribution of cells in the different cell cycle phases using flow cytometry. The miR-146b overexpressing cells showed a substantial decrease in the numbers of cells in S phase and an increased number in G1 phase compared with negative control cells (Fig. 4B) . This suggests that the miR-146b inhibition of human preadipocyte growth results from an arrest in G0/G1 phase.
Overexpression of miR-146b directly inhibits KLF7 mRNA expression via interaction with its 3 0 -UTR region
To explore how miR-146b affects human preadipocyte adipogenesis, we used three computational prediction programs: TargetScan, PicTar and miRanda to select putative target mRNAs. Of the commonly screened genes, KLF7 had a high score for binding to miR-146b, and has previously been associated with human adipocyte proliferation and differentiation (Kanazawa et al., 2005; Kawamura et al., 2006; Zhang et al., 2013) .
To determine whether miR-146b affects KLF7 expression, we performed qRT-PCR and western blot on cultured miR-146b upand down-regulating human preadipocytes at different time points during adipogenesis, and the results indicated that miR-146b significantly inhibits KLF7 mRNA expression, especially at day 7 and day 10 (Fig. 5) .
KLF7 mRNA has a long 3 0 UTR of 423 bp and has a predicted miR146b interaction site at position 105-111. To test if this sequence specifically contributes to the miR-146b-mediated regulation of KLF7 mRNA expression, we generated a luciferase reporter vector containing the full 3 0 UTR segment. Transient cotransfection of the miR-146b overexpression vector and the W.T.KLF7-3 0 UTR luciferase expression plasmid in HEK293T cells demonstrated a direct binding of miR-146b to the KLF7 3 0 UTR, resulting in a significant decrease in luciferase activity (Fig. 6A) . To exclude the possibility of non-specific interaction, we generated an additional reporter plasmid M.T.KLF7-3 0 UTR in which the 'seed' match region was mutated by changing five nucleotides to disrupt the putative interaction of KLF7 mRNA with miR-146b (Fig. 6B) . As shown in Fig. 6A , strong luciferase activity was still observed in the group of cells transfected with the M.T.KLF7-3 0 UTR vector regardless of miR-146b abundance. These findings indicate that miR-146b interacts with the KLF7 3 0 UTR to regulate KLF7 mRNA expression levels.
Dysregulation of miR-146b and KLF7 in high fat induced obese mice
Abnormal miR-146b expression has been reported in the adipose tissue of diet-induced obese mice (Bengestrate et al., 2011; Chartoumpekis et al., 2012) , but this research was limited to epididymal white adipose tissue. We investigated whether the levels of miR-146b are altered in subcutaneous white adipose tissue and brown adipose tissue. In this study, the diet-induced obese (DIO) mice gain significantly more body weight (Fig. S1A ) and became less glucose tolerant and severely insulin resistant by the end of the experiment (Fig. S1B and C) as compared with the NCD group. As expected, the miR-146b expression level in epididymal white adipose tissue (eWAT) was much higher in the HFD group mice. MiR-146b was down-regulated in the brown fat tissue (BAT) of HFD fed obese mice compared with NCD fed lean mice, but there were no significant differences in miR-146b expression levels in the subcutaneous white fat tissues (sWAT) of the two groups of mice (Fig. 7A) . At the same time, we investigated the KLF7 gene expression and found KLF7 was obviously down-regulated in eWAT of HFD mouse, but it was with no difference in sWAT as the miR-146b expression (Fig. 7B) . 
Altered expression of miR-146b and KLF7 in visceral and subcutaneous adipose tissues from human overweight and obese subjects
Since miR-146b expression increases during adipogenesis and affects human preadipocyte adipogenesis, we hypothesized that miR-146b levels might be selectively evaluated within obese states. To test these possibilities, visceral fat tissue samples were obtained from the greater omentum tissues of 13 lean and 11 overweight or obese subjects, and subcutaneous fat tissue samples were isolated from 14 lean and nine overweight or obese subjects (Table 2) . MiR-146b levels were measured in these tissue samples. The expression of miR-146b in visceral fat tissue samples from the overweight or obese group was higher than in the tissue samples from the lean group (Fig. 8A ) and there was a slightly positive correlation between miR-146b levels and BMI with R 2 = 0.372 and p = 0.073 (Fig. 8B) . MiR-146b levels were significantly higher in the subcutaneous fat tissue of the overweight or obese subjects (Fig. 8C) , and were positively correlated with BMI with R 2 = 0.44 and p = 0.035 (Fig. 8D) . These results indicated a link between the degree of obesity and miR146b level. We also measured the KLF7 gene expression in human subjects and the results showed that KLF7 in visceral fat tissues of overweight or obese group was lower than that of lean group (Fig. 9A) . Interestingly, there was no difference in subcutaneous fat tissue between these two groups (Fig. 9B) , since higher miR146b level was showed in overweight or obese subjects. Thus, miR-146b may affect human visceral obesity by inhibiting KLF7.
Discussion
We have demonstrated that miR-146b is a novel regulator of human visceral preadipocyte proliferation and differentiation. We found that miR-146b was gradually expressed during human adipogenic differentiation, and gain-and loss-of-function studies in human preadipocytes suggested that miR-146b not only inhibited cell proliferation but also promoted cell differentiation. In addition, miR-146b expression was altered in adipose tissues from human overweight and obese subjects and DIO mice. These findings indicate that miR-146b acts as positive regulator of adipogenesis in human visceral preadipocytes.
MiRNAs function by targeting one or more specific mRNAs (Bartel, 2004) . We searched for the potential targets of miR-146b with bioinformatics software which revealed a potential binding site in the 3 0 UTR of the Kruppel-like factor 7 (KLF7) gene. The inhibitory effects of miR-146b on KLF7 expression and assay with a firefly luciferase reporter indicate experimentally that in human visceral adipocytes KLF7 is a direct target of miR-146b.
KLF7 is a member of the KLF family of transcription factors. Overexpression of KLF7 in human preadipocytes (Kawamura et al., 2006) or 3T3-L1 preadipocytes (Kanazawa et al., 2005) suppresses adipogenesis and inhibits the expression of the adipogenic transcription factors C/EBPa and PPARc and adipocyte-marker genes, such as the AP2 gene. Furthermore, KLF7 affects insulin sensitivity via different mechanisms in different tissues: by regulating adipocytokine gene expression in mature adipocytes, inhibiting insulin secretion in pancreatic b cells and suppressing hexokinase 2 gene expression in muscle cells (Kawamura et al., 2006) . SNP analysis of a larger cohort of Japanese subjects has implicated the KLF7 in the pathogenesis of type 2 diabetes (Kanazawa et al., 2005) . In addition, a novel KLF7 SNP variant may protect against obesity in the Danish population (Zobel et al., 2009) . However, the upstream mechanisms of KLF7 regulation in adipogenesis are not known. In our study, we demonstrated that miR-146b is a negative regulator of KLF7 during adipocyte proliferation and differentiation. Just when we prepared this paper, a research took on 3T3-L1 reported that miR-146b could promote adipogenesis by targeting the SIRT1 (Ahn et al., 2013) . In this point, the promotion of adipogenesis by miR-146b is the same with each other although cells of different species were used, indicating that the function of miR-146b was conserved. Additionally, in our study, miR-146b could inhibit human preadipocyte proliferation by affecting cell cycles. When came to targets, SIRT1 was proved to be possible target in 3T3-L1 preadipocyte, but KLF7 in human visceral preadipocyte. In this case, there are two possibilities to explain the difference. One is that the variation is resulting from difference between species, and another may be due to that miR-146b can exert the action through binding one or more target genes to fine tune the adipogenesis process. Interestingly, the KLF7 level also decreased in epididymal white adipose tissue of DIO mouse, indicating that KLF7 may be a target in 3T3-L1 cell lines. Thus, further experiments will be necessary to dissect the possibility in different adipocyte lines and gain more information about miR-146b roles during adipogenesis.
The DIO mouse is an in vivo model that mimics common human obesity more accurately than single-gene mutation lines, such as the ob/ob mouse. We used DIO mice to demonstrate the changes Data are expressed as mean ± SD. * P < 0.05. ** P < 0.001. Fig. 8 . MiR-146b is up-regulated in visceral and subcutaneous fat tissues of human overweight and obese subjects. MiR-146b expression levels in visceral and subcutaneous fat tissues from lean and overweight/obese subjects were determined by qRT-PCR analysis. The results showed that miR-146b expression in visceral (A) and subcutaneous (B) fat tissues significantly increased in overweight and obese relative to lean subjects. Linear regression analysis indicated positive relationships between tissue miR-146b levels and the BMIs of the subjects for visceral fat tissues (C) and subcutaneous fat tissues (D).
of miR-146b expression patterns in obesity. In the HFD mice, elevated miR-146b levels in epididymal white adipose tissue were found, as has been previously reported (Ahn et al., 2013; Bengestrate et al., 2011; Chartoumpekis et al., 2012) . However, we did not observed the expected differences in miR-146b expression in the subcutaneous white fat tissues between the two groups. Brown adipose tissue is of interest in metabolism research due to its ability to consume calories without producing harmful metabolic waste. The presence of brown fat has been demonstrated in adult humans (Frontini and Cinti, 2010 ) making this tissue a potential target for the treatment of obesity and metabolic syndrome (Nedergaard and Cannon, 2010) . We tested whether miR-146b levels were altered in brown adipose tissue and observed downregulated levels, which was opposite to the change observed in epididymal white adipose tissue, suggesting that miR-146b may function differently in brown fat tissue to influence the occurrence and development of mouse obesity. The differences in the observed expression level changes in these three types of fat tissue could reflect the depot-specific characteristics of body fat tissues.
We investigated whether the miR-146b expression in adipose tissue is altered in obese humans. MiR-146b expression was significantly increased in omental fat tissue, and up-regulated in the subcutaneous fat tissue of overweight and obese subjects as compared with the equivalent tissues in lean subjects. As miR-146b promotes visceral preadipocyte adipogenesis, the result was consistent with our expectations.
The fat tissues of obese subjects can create an inflammatory state (Rausch et al., 2008; Trayhurn et al., 2008) and adipocytes are involved as they produce several proinflammatory cytokines, including monocyte chemoattract protein-1 (MCP-1), that can induce macrophage infiltration and activation in adipose tissues (Sell and Eckel, 2007) Macrophages are an important source of the inflammatory cytokines TNF-a and IL-6 (Finucane et al., 2012) , which can induce miR-146b expression in human mature adipocytes (Shi et al., 2014) . If it is indeed the case that miR146b can promote the proliferation and differentiation of preadipocytes into mature adipocytes, miR-146b expression will lead to fat tissues that are capable of increased lipid accumulation and increased obesity. This increased volume of fat tissue will increase the secretion of inflammatory factors. Thus, a positive feedback loop can be hypothesized to exist between miR-146b and the inflammatory cytokines that will exacerbate obesity and metabolic dysfunction. However, miR-146b has also been demonstrated to have anti-inflammatory properties (Curtale et al., 2013; Hulsmans et al., 2012) , so the validity of this theory in vivo will need further investigation. to knockdown miR-146b in obese mice for 3 days, and found that these mice lost weight and showed an improvement of their metabolic disorders, without any evidence of hepatotoxicity (Ahn et al., 2013) . This result suggests that miR-146b could be a potential target for treating obesity. However, efforts to reduce the in vivo activity of miR146b should proceed with caution due to its anti-inflammatory action in human monocytes.
Conclusion
In the present study, miR-146b functions as a novel regulator of human visceral preadipocyte proliferation and differentiation by its targeting of the KLF7 gene. MiR-146b is significantly differentially expressed in visceral fat tissues in obese and lean subjects, and could be a therapeutic target against obesity and the metabolic syndrome.
